cyrilzakka/clinical-trials huggingface dataset:
Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial

Up to one-third of common warts can remain recalcitrant, an occurrence that has been attributed to impaired cell-mediated immunity. At present, no guidelines exist for the management of recalcitrant cutaneous warts. Zinc, a well-established immunomodulatory agent, has shown promise in this regard. Previous studies documenting the efficacy of oral zinc used zinc sulfate given at a maximum dose of 600 mg/day, equivalent to 140 mg of elemental zinc, which is over three times the recommended upper limit of 40 mg of elemental zinc per day. This raises concerns over safety and tolerability. In the Philippines, oral zinc is more widely available in chelated forms such as zinc gluconate, which have the benefit of improved absorption compared to non-chelated compounds such as zinc sulfate. This study will seek to determine if zinc gluconate 300 mg/day, equivalent to 40 mg of elemental zinc, will be efficacious in treating recalcitrant cutaneous warts. This lowered dose may have the added benefits of increased safety, tolerability, and cost-effectiveness.


Eligibility Criteria:
Inclusion Criteria:

1. Male or non-pregnant female
2. Age 19 years and older
3. With ≥ one (1) recalcitrant common, mosaic, palmar, plantar, or periungual wart/s
4. Consent given

Exclusion Criteria:

1. Current or history of mental illness
2. Current or history of malignancy
3. Severe immunodeficiency states
4. Pregnant or lactating
5. Documented adverse effects to oral or topical zinc exposure
6. Oral intake of zinc supplements in the past 12 months or less
7. Oral Intake of H2 antagonists in the past 4 weeks or less
8. Oral intake of immunosuppressives in the past 4 weeks or less
9. Concurrent usage of other treatment modalities
10. Current anogenital warts
Trial of SAVVY and HIV in Ghana

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 35 year old women
* HIV negative
* More than one sexual partner in past 3 months
* Average of 3 coital acts per week
* Willing to use vaginal gel and condoms for 12 months

Exclusion Criteria:

* HIV positive
* Pregnant
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

* Cohort 1: To evaluate the drug interactions, safety, and tolerability of oral edaravone when coadministered with rosuvastatin, sildenafil or furosemide in healthy adult males
* Cohort 2: To evaluate the pharmacokinetics, safety, and tolerability of oral edaravone in healthy Japanese and Caucasian adult males


Eligibility Criteria:
Inclusion Criteria:

* Healthy adult male volunteers
* Cohort 1: Japanese, Cohort 2: Japanese or Caucasian
* Subjects aged between 20 and 45 years at the time of informed consent
* Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

* Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
* Body mass index (BMI) of \<18.0 or \>30.0, or body weight of \<50 kg (BMI formula: body weight \[kg\]/height \[m\]2, rounded to one decimal place)
* Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs
* Subjects who do not agree to use an effective method of contraception from initiation of study drug administration to 14 days after completion (discontinuation) of study drug administration
* Subjects who have previously received edaravone
* Subjects who have participated in another clinical study and received a study drug within 12 weeks before providing informed consent
* Use of any drug(s) other than the study drug or as-needed use of acetylsalicylic acid within 7 days before the initiation of study drug or victim drug administration
* Use of any alcohol, xanthine, or caffeine-containing product(s) within 24 hours before screening and Day -1 visiting
* Use of any supplement(s) within 7 days before the initiation of study drug or victim drug administration
* Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances during the following periods (Cohort 1: within 7 days before the initiation of victim drug administration, Cohort 2: within 24 hours before each Day -1 visiting)
* Use of any tobacco or nicotine-containing product(s) (Cohort 1: within 12 weeks before the initiation of victim drug administration during the following periods, Cohort 2: within 24 hours before each Day -1 visiting)
* Use of any health food(s) containing St John's Wort (Hypericum perforatum) within 2 weeks before the initiation of victim drug administration (only in Cohort 1)
Employee Wellness Survey

The aims of this study are 1) To assess the prevalence of tobacco use and cessation treatment preferences among YKHC employees, 2) To assess employee's current levels of perceived stress, engagement in physical activity, and feelings of resiliency to inform future tobacco cessation interventions, and to examine the relationship between these factors and tobacco use, and 3) To assess YKHC employees' perceptions and opinions of the hospital's current workplace tobacco policy and expansion of these regulations to all YKHC properties.

All employees at YKHC will be invited to complete an online survey that took approximately 10-15 minutes to complete. All employees will receive information via email, which includes an overview of the project, information regarding privacy and consent, and a link to the survey. Those who wish to do so were able to print a copy of the information for their reference. Employees who wish to participate did so by clicking on the survey link. Those who do not wish to participate could simply delete the email. Participants will be given two weeks to complete the online survey. Individuals who do not respond within the first week, will be sent an automated email reminder. All employees who participate will received a small incentive (approximately $10 in value).

Eligibility Criteria:
Inclusion Criteria:

* YKHC employee
* aged 18 years or older
* provides consent

Exclusion Criteria:

* None
Clinical Performance of Habitual Hydrogel vs. Silicone Hydrogel Toric Contact Lenses

Evaluate the clinical performance of existing wearers of hydrogel toric lenses when refitted with Avaira toric silicone hydrogel contact lenses over 1 week of wear.

This is a 60-subject, single masked, bilateral, parallel study design comparing the fitting characteristics of enfilcon A toric lenses against the subjects habitual hydrogel toric lenses (omafilcon A, ocufilcon D or methafilcon B wearers). Subject's habitual toric lenses will be evaluated at the first visit and then re-fitted with a pair of Avaira toric lenses. After 1 week of daily wear, subjects will return for a second and final evaluation.

Eligibility Criteria:
Inclusion Criteria:

* Is between 18 and 40 years of age (inclusive)
* Has had a self-reported visual exam in the last two years
* Is an adapted soft toric contact lens wearer
* Has a contact lens spherical prescription between +6.00 to - 8.00 (inclusive)
* Have no less than 0.75D of astigmatism and no more than 1.75 D in both eyes.
* Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye.
* Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses.
* Has clear corneas and no active ocular disease
* Has read, understood and signed the information consent letter.
* Patient contact lens refraction should fit within the available parameters of the study lenses.
* Is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so).
* Is willing to comply with the visit schedule

Exclusion Criteria:

* Has a contact lens prescription outside the range of the available parameters of the study lenses.
* Has a spectacle cylinder less than -0.75D or more than -1.75D of cylinder in either eye.
* Has a history of not achieving comfortable contact lens wear (5 days per week; \> 8 hours/day)
* Has contact lens best corrected distance vision worse than 20/25 (0.10 logMAR) in either eye.
* Presence of clinically significant (grade 2-4) anterior segment abnormalities
* Presence of ocular or systemic disease or need of medications which might interfere with contact lens wear.
* Slit lamp findings that would contraindicate contact lens wear such as:

  * Pathological dry eye or associated findings
  * Pterygium, pinguecula, or corneal scars within the visual axis
  * Neovascularization \> 0.75 mm in from of the limbus
  * Giant papillary conjunctivitis (GCP) worse than grade 1
  * Anterior uveitis or iritis (past or present)
  * Seborrheic eczema, Seborrheic conjunctivitis
  * History of corneal ulcers or fungal infections
  * Poor personal hygiene
* Has a known history of corneal hypoesthesia (reduced corneal sensitivity)
* Has aphakia, keratoconus or a highly irregular cornea.
* Has Presbyopia or has dependence on spectacles for near work over the contact lenses.
* Has undergone corneal refractive surgery.
* Is participating in any other type of eye related clinical or research study.
Function Integrity of Neck Anatomy in Thyroid Surgery

Recent trends in the management of patients with low-risk papillary thyroid carcinoma who have a nonsuspicious or cytologically benign contralateral nodule call into question the need for routine total thyroidectomy. Although the lobectomy for the unilateral thyroid cancer with contralateral benign nodules is sufficient treatment, some of the patients might suffer from the anxiety of the residual benign thyroid nodule and tend to choose total thyroidectomy, which might be overtreatment.

Thermal ablation has been proven to be effective in achieving nodule shrinkage and being also free from major complications. In our institution, intraoperative RFA was a proposed alternative strategy to treat the contralateral benign nodules after the thyroid lobectomy for the malignant lobe, which was found to have a better quality of life on anxiety, physiological health, social family, psychological and sensory mentions with a considerable complication rate.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with unilateral thyroid carcinoma and contralateral benign nodule confirmed by preoperative ultrasound-guided fine-needle aspiration cytology;
* Patients with contralateral nodules ≤ 20mm and located in the thyroid gland;
* Patients with clinical node-negative cervical compartment at palpation and neck ultrasound.

Exclusion Criteria:

* Previous history of neck surgery
* Previous history of neck radiation therapy
Gut Microbiome in Orthopaedics: Revision Total Knee Arthroplasty

Many patients who receive knee replacement surgery must return for a revision (or repeat) surgery due to ongoing pain, stiffness, infection, or implant loosening. The role of the gut microbiome-the collection of bacteria and other microbes within the human gastrointestinal tract-is just beginning to be recognized in orthopaedics. The gut microbiome has been found to affect the immune response and bone regulation, potentially contributing to infection or loosening after total joint replacement. Antibiotics are regularly used in orthopaedic surgery to reduce the risk of infection, yet they might also harm gut microbiota and reduce their potentially beneficial effects. As a result, understanding the relationship between gut microbiota and surgical outcomes has become increasingly important. Therefore, this study aims to determine if there are differences in gut microbiota composition between patients with well-functioning knee replacements and those requiring revision knee replacements. Additional study aims include assessing inflammation, implant loosening, metal ion levels, and circulating bacteria in blood or tissue between well-functioning or failed knee replacements.


Eligibility Criteria:
Inclusion Criteria:

* Scheduled to undergo a revision TKA
* Willing and able to comply with follow-up requirements
* Ability to provide informed consent
* Ability to read, write, and speak English

Exclusion Criteria:

* Pregnancy
* Less than 3 months post-operation from primary surgery
* Diagnosis of periprosthetic fracture
* Scheduled for DAIR (debridement, antibiotics, and implant retention) revision surgery
* Scheduled for stage 2 PJI revision
Brain-to-brain Synchrony in Ss With Different Levels of Social Interaction

Brain-to-brain synchrony will be measured between pairs of subjects with different levels of similarity of DNA and social interactions

Brain-to-brain synchrony will be measured in five pairs of identical twins, five pairs who are good friends and from the same region of a country, and five pairs of strangers from different countries when they practice Transcendental Meditation practice

Eligibility Criteria:
Inclusion Criteria:

* healthy fit the cohort criteria practice TM

Exclusion Criteria:

* mental or physical issue
Optimized Programming in Spinal Cord Stimulation (SCS) System

The objective of this study is to evaluate extent, location, and perception of paresthesia as a function of anode/cathode configuration.

The clinical results from this study may help to validate predictions made by mathematical models of neurons that are activated by SCS and increase scientific knowledge about the way in which different programs relate to satisfactory outcomes, such that use of the model may help in the development of new products.

Eligibility Criteria:
Inclusion Criteria:

* Be previously implanted with Precision SCS System (3-36 months post permanent implant) having 2 parallel percutaneous leads placed between T8-T10.
* Be implanted with Precision SCS System for the treatment of neuropathic pain of trunk and/or limbs
* Be 18 years of age or older
* Be extremely satisfied, very satisfied, or satisfied with SCS therapy for treatment of pain condition
* Be able to use pen tablet to document regions of paresthesia and pain
* Be able to lie in the supine position for 45 minutes at a minimum
* Be able to verbally report qualitative and quantitative aspects of paresthesia sensations.
* Have a paresthesia threshold on a standard program below 4mA while in the supine position
* Have at minimum the upper contact of one lead below T8 and the lower contact above T11 vertebral levels
* Be willing and able to comply with study-related procedure
* Agree to study requirements and provides written Informed Consent

Exclusion Criteria:

* Unable to read, write, speak, and understand English
* Currently pregnant or planning to become pregnant during the course of the study
* Have negative finding in any of the pre-screening and screening requirements
* Upon fluoroscopy, location of both leads is identified to be outside T8-T10 vertebral levels
* Unable to perceive the sensation of paresthesia associated with stimulation in the trunk and/or lower extremities
* Have a drug pump and/or a non-Precision neurostimulation device (regardless of whether active or inactive)
* Have had any interventional pain procedure or surgeries (including Interlaminar epidural steroid injection, Transforaminal epidural steroid injection, Caudal epidural steroid injection, Selective nerve root block, Intraarticular lumbar facet injection, Sacroiliac joint injection, Piriformis muscle injection, Trochanteric bursa injection, Hip/knee joint injections, Medial branch block (innervates facet joint), Pulsed radiofrequency neurotomy medial branches, Pulsed radiofrequency dorsal root ganglion, Thermal (high temperature) radiofrequency neurotomy medial branches, Trigger point injections, and Botulinum toxin injections) involving the spine within the past 30 days
* Have any condition that is likely to confound evaluation of study endpoints. Conditions that may make paresthesia coverage variable over the course of the study include multiple sclerosis, partial spinal cord injury, diabetic peripheral neuropathy, peripheral vascular disease, scoliosis, deafferentation, etc.
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease

It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.

Eligible subjects of the study will be randomly assigned into four groups at a ratio of 1:1:1:1: three treatment groups and one placebo group. The subjects will take trial drugs orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours.

Eligibility Criteria:
Inclusion Criteria:

1. Male/female patients with early Parkinson's disease who are over 30 years old and under 75 years old (including cut-off values).
2. Able to understand and willing to sign an informed consent form (ICF) voluntarily.
3. The diagnosis of Parkinson's disease complies with idiopathic Parkinson's disease (2015 version of MDS Parkinson's disease diagnostic criteria).
4. Modified Hoehn and Yahr Scale≥1, ≤2.5 points.
5. Agree to use medically acceptable contraceptive methods throughout the study and within 1 month after completing the study.

Exclusion Criteria:

1. Have a history of severe allergic reactions or allergies to levodopa or carbidopa.
2. Pregnancy or breastfeeding.
3. Diagnosed as atypical Parkinson's disease or any known secondary Parkinson's syndrome.
4. The investigator believes that the placebo treatment cannot be tolerated.
5. Acute psychosis or hallucinations, using any antipsychotic to treat psychosis or clinically obvious depression.
6. History of epilepsy or epilepsy.
7. The history of narrow-angle glaucoma.
8. Subjects with a history of malignant melanoma.
9. Patients with obvious cognitive impairment.
10. The investigator believes that there are clinically significant medical or surgical diseases and patients who are not suitable for participating in clinical trials.
Korean Hereditary Breast Cancer Study

1. To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients with family history of breast/ovarian cancer.
2. To evaluate the prevalence of BRCA1/2 mutation of breast cancer patients without family history, but high risk of hereditary cancer.
3. To evaluate the prevalence of BRCA1/2 mutation of family member of BRCA1/2 mutation.
4. To evaluate the prevalence of ovarian cancer of population of above 3 groups.

1. To find founder mutation in Korean
2. To correlation prevalence with risk evaluation
3. To find risk factors concerning life style

Eligibility Criteria:
Inclusion Criteria:

* Over 19 years old
* Agree to this study
* Breast cancer patient with family history of breast/ovarian cancer (1 subgroup)
* Breast cancer patient; young age (\<40), bilateral, male, combined ovarian (2 subgroup)
* Family members with 1, 2 subgroups (3 subgroup)

Exclusion Criteria:

* Under 20 years old
* Unable to decide for oneself
Intrathecal Additives to Prevent Post Spinal Shivering in Transurethral Prostatectomy

Spinal anesthesia is the technique of choice in transurethral prostatectomy.However,one of the common complications of spinal anesthesia is shivering which is even exaggerated in patients undergoing transurethral prostatectomy.this high incidence is most probably caused by sympathetic block and use of large amount of irrigation fluid during surgery.There are two methods to reduce shivering.Previous studies showed that intrathecal fentanyl is an appropriate method to reduce shivering.Intrathecal dexamethasone could reduce shivering by regulating immune responses.

Shivering is an involuntary repetitive contractions of skeletal muscles that increases the basal metabolism and is considered to be a defense mechanism for regulating body temperature in adults .

Post spinal shivering may cause discomfort to the patient,and may aggravate wound pain by stretching incisions and increases intracranial and intra ocular pressure.Shivering may increase tissue oxygen demand as much as 500% and is accompanied by increase in minute ventilation and cardiac output to maintain aerobic metabolism.

Tympanic temperature will be recorded preoperatively,after establishment of spinal anesthesia,and every 15 minutes til the end of operation.Core temperature below 36.5 C is considered as hypothermia Shivering intensity will be assessed with a five -point scale validated by Crossly and Maharaj.

Adverse events like hypotension,bradycardia, respiratory depression,nausea and vomiting will be recorded and treated.

Eligibility Criteria:
Inclusion Criteria:

* ASA(American society of anesthesiologists) physical status grade I-II
* BMI(body mass index) less than 35 kg/m2
* patients undergoing transurethral prostatectomy

Exclusion Criteria:

* patient refusal.
* patients with contraindications to spinal anesthesia e.g coagulopathy,anti coagulant therapy,allergy to local anesthetic,psychological disorders,...
* patient with advanced cardiopulmonary diseases or thyroid diseases.
* patients on corticosteroids therapy or on Alpha2 blocker orAlcohol.
* patients with initial body temperature above 37.5 C or below 36.5 C.